Colorectal Cancer Clinical Trial
Official title:
Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer
More than one third of patients with colorectal cancer (CRC) suffer from comorbidity such as heart and lung diseases. This comorbidity markedly impairs survival after surgical treatment owing to increased mortality within the first weeks to months after surgery. Since the operation itself constitutes a severe challenge to the patient's cardiopulmonary system, this study aims to elucidate whether a more systematic perioperative management and follow-up of colorectal cancer patients with cardiopulmonary comorbidity may improve their outcome as measured by complications, hospitalisation times, and survival.
Background and overview
More than one third of patients with colorectal cancer (CRC) suffer from comorbidity such as
heart and lung diseases. This comorbidity markedly impairs survival after surgical treatment
owing to increased mortality within the first weeks to months after surgery, and this
increased mortality is related to medical complications such as heart and lung complications.
Since the operation itself constitutes a severe challenge to the patient's cardiopulmonary
system, this study aims to elucidate whether a more systematic perioperative management and
follow-up of colorectal cancer patients with cardiopulmonary comorbidity may improve their
outcome as measured by complications, hospitalisation times, and survival within the first
year.
All patients scheduled for elective surgical treatment of colorectal cancer at Vejle Hospital
are screened by a study nurse for cardiopulmonary comorbidity to determine their eligibility
for inclusion. If they fulfil inclusion criteria, they are seen preoperatively by a
cardiologist and/or a pulmonary physician and undergo echocardiography and/or spirometry.
Included patients are randomized postoperatively to either standard follow-up alone
("standard" group) or standard follow-up supplemented with structured medical management and
follow-up ("intervention" group). Patients in the intervention group are examined on the 4th
or 5th postoperative day by an experienced physician from the Department of Internal
Medicine. Furthermore, the intervention group is followed up at outpatient visits 1 and 3
months postoperatively. The 1-month visit includes a cardiology visit with echocardiography
and ECG, and a pulmonary medicine visit with spirometry. The 3-month visit includes only a
pulmonary medicine visit with spirometry.
Mortality, cardiopulmonary complications, hospitalisation time and treatment changes induced
by the structured follow-up will be recorded as outcome measures for the intervention.
Hypothesis
Patients with cardiopulmonary comorbidity who have their standard follow-up extended to
include a structured medical management and follow-up after surgery for colorectal cancer
obtain a better outcome as measured by less cardiopulmonary morbidity and better survival
within the first year.
Aim
To test a study design with systematic preoperative screening for cardiopulmonary comorbidity
and postoperative randomization of eligible patients to either standard followup alone or
standard follow-up supplemented with structured medical management and follow-up after
operation for colorectal cancer.
Design
A randomized feasibility study. Based on older data, it will require approximately 400
patients in each arm to demonstrate a 10 % reduction in the expected mortality. This study
aims to test the design and acquire more reliable mortality data in each arm in order to
establish the basis for a larger multicentre study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |